1
|
Vanka R, Kuppusamy G, Praveen Kumar S, Baruah UK, Karri VVSR, Pandey V, Babu PP. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers. J Microencapsul 2018; 35:121-136. [PMID: 29448884 DOI: 10.1080/02652048.2018.1441915] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Cerebral malaria (CM) is a fatal neurological complication of Plasmodium falciparum infection that affects children (below five years old) in sub-Saharan Africa and adults in South-East Asia each year having the fatality rate of 10-25%. The survivors of CM also have high risk of long term neurological or cognitive deficits. The objective of the present investigation was to develop optimised nanostructured lipid carriers (NLCs) of artemether (ARM) for enhanced anti-malarial efficacy of ARM. NLCs of ARM were prepared by a combination of high speed homogenisation (HSH) and probe sonication techniques. Preliminary solubility studies for ARM showed highest solubility in trimyristin (solid lipid), capmul MCM NF (liquid lipid) and polysorbate 80 (surfactant). Trimyristin and capmul showed superior miscibility at a ratio of 70:30.The optimised NLC formulation has the particle size (PS) of: 48.59 ± 3.67 nm, zeta potential (ZP) of: -32 ± 1.63 mV and entrapment efficiency (EE) of: 91 ± 3.62%. In vitro cell line (human embryonic kidney fibroblast cell line (HEK 293 T)) cytotoxicity studies showed that prepared formulation was non-toxic. The results of in vivo studies in CM induced mice prevented the recrudescence of parasite after administration of NLCs of ARM. Additionally, NLCs of ARM showed better parasite clearance, higher survival (60%) in comparison to ARM solution (40%). Also it was observed that lesser entrapment of Evans blue stain (prepared in PBS as solution) in the NLCs of ARM treated brains of C57BL/6 mice than ARM solution treated mice. Hence NLCs of ARM may be a better alternative for improving therapeutic efficacy than ARM solution.
Collapse
Affiliation(s)
- Ravisankar Vanka
- a Department of Pharmaceutics, JSS College of Pharmacy, Ooty , Jagadguru Sri Shivarathreeswara University , Mysuru , India
| | - Gowthamarajan Kuppusamy
- a Department of Pharmaceutics, JSS College of Pharmacy, Ooty , Jagadguru Sri Shivarathreeswara University , Mysuru , India
| | - Simhadri Praveen Kumar
- b Department of Biotechnology and Bioinformatics, School of Life Sciences , University of Hyderabad , Hyderabad , Telangana , India
| | - Uday Krishna Baruah
- a Department of Pharmaceutics, JSS College of Pharmacy, Ooty , Jagadguru Sri Shivarathreeswara University , Mysuru , India
| | | | - Vimal Pandey
- b Department of Biotechnology and Bioinformatics, School of Life Sciences , University of Hyderabad , Hyderabad , Telangana , India
| | - Phanithi Prakash Babu
- b Department of Biotechnology and Bioinformatics, School of Life Sciences , University of Hyderabad , Hyderabad , Telangana , India
| |
Collapse
|
2
|
Sidhaye AA, Bhuran KC, Zambare S, Abubaker M, Nirmalan N, Singh KK. Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes. Nanomedicine (Lond) 2016; 11:2809-2828. [PMID: 27759489 DOI: 10.2217/nnm-2016-0235] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
AIM The intra-erythrocytic development of the malarial parasite is dependent on active uptake of nutrients, including human serum albumin (HSA), into parasitized red blood cells (pRBCs). We have designed HSA-based nanoparticles as a potential drug-delivery option for antimalarials. METHODS Artemether-loaded nanoparticles (AANs) were designed and antimalarial activity evaluated in vitro/in vivo using Plasmodium falciparum/Plasmodium berghei species, respectively. RESULTS Selective internalization of AAN into Plasmodium-infected RBCs in preference to healthy erythrocytes was observed using confocal imaging. In vitro studies showed 50% dose reduction for AAN as compared with drug-only controls to achieve IC50 levels of inhibition. The nanoparticles exhibited twofold higher peak drug concentrations in RBCs with antimalarial activity at 50% of therapeutic doses in P. bergei infected mice. CONCLUSION Novel HSA-based nanoparticles offer safe and effective approach for selective targeting of antimalarial drugs.
Collapse
Affiliation(s)
- Aditi A Sidhaye
- CU Shah College of Pharmacy, SNDT Women's University, Santacruz (W), Mumbai 400049, India
| | - Kanchan C Bhuran
- CU Shah College of Pharmacy, SNDT Women's University, Santacruz (W), Mumbai 400049, India
| | - Sneha Zambare
- CU Shah College of Pharmacy, SNDT Women's University, Santacruz (W), Mumbai 400049, India
| | - Munna Abubaker
- School of Environment & Life Sciences, University of Salford, Manchester, M5 4WT, UK
| | - Niroshini Nirmalan
- School of Environment & Life Sciences, University of Salford, Manchester, M5 4WT, UK
| | - Kamalinder K Singh
- CU Shah College of Pharmacy, SNDT Women's University, Santacruz (W), Mumbai 400049, India.,School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston, PR1 2HE, UK
| |
Collapse
|
3
|
Prabhu P, Suryavanshi S, Pathak S, Patra A, Sharma S, Patravale V. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria. Int J Pharm 2016; 513:504-517. [PMID: 27596113 DOI: 10.1016/j.ijpharm.2016.09.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 08/28/2016] [Accepted: 09/02/2016] [Indexed: 12/14/2022]
Abstract
Patients with cerebral malaria (CM) are unable to take oral medication due to impaired consciousness and vomiting thus necessitating parenteral therapy. Quinine, artemether, and artesunate which are currently used for parenteral malaria therapy have their own drawbacks. The World Health Organization (WHO) has now banned monotherapy and recommends artemisinin-based combination therapy for malaria treatment. However, presently there is no intravenous formulation available for combination therapy of malaria. Artemether-Lumefantrine (ARM-LFN) is a WHO approved combination for oral malaria therapy. However, the low aqueous solubility of ARM and LFN hinders their intravenous delivery. The objective of this study was to formulate ARM-LFN nanostructured lipid carriers (NLC) for intravenous therapy of CM. ARM-LFN NLC were prepared by microemulsion template technique and characterized for size, drug content, entrapment efficiency, drug release, crystallinity, morphology, amenability to autoclaving, compatibility with infusion fluids, stability, antimalarial efficacy in mice, and toxicity in rats. The ARM-LFN NLC showed sustained drug release, amenability to autoclaving, compatibility with infusion fluids, good stability, complete parasite clearance and reversal of CM symptoms with 100% survival in Plasmodium berghei-infected mice, and safety in rats. The biocompatible ARM-LFN NLC fabricated by an industrially feasible technique offer a promising solution for intravenous therapy of CM.
Collapse
Affiliation(s)
- Priyanka Prabhu
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga, Mumbai 400019, Maharashtra, India
| | - Shital Suryavanshi
- Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400005, Maharashtra, India
| | - Sulabha Pathak
- Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400005, Maharashtra, India
| | - Aditya Patra
- Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400005, Maharashtra, India
| | - Shobhona Sharma
- Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400005, Maharashtra, India
| | - Vandana Patravale
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga, Mumbai 400019, Maharashtra, India.
| |
Collapse
|
4
|
Artemetherlumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency. Int J Pharm 2016; 511:473-487. [DOI: 10.1016/j.ijpharm.2016.07.021] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 07/10/2016] [Accepted: 07/11/2016] [Indexed: 11/20/2022]
|
5
|
Ibrahim N, Ibrahim H, Sabater AM, Mazier D, Valentin A, Nepveu F. Artemisinin nanoformulation suitable for intravenous injection: Preparation, characterization and antimalarial activities. Int J Pharm 2015; 495:671-9. [PMID: 26383839 DOI: 10.1016/j.ijpharm.2015.09.020] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 09/10/2015] [Accepted: 09/11/2015] [Indexed: 02/02/2023]
Abstract
More than 40 years after its discovery, artemisinin has become the most promising antimalarial agent. However, no intravenous formulation is available due to its poor aqueous solubility. Here, we report the preparation, characterization, and in vitro and in vivo biological evaluation of biodegradable albumin-bound artemisinin nanoparticles. The nanoparticles were prepared by a combination of a bottom-up and a top-down processes and characterized by different spectroscopic techniques. The preparation process was optimized to develop a nanoformulation with the smallest possible diameter and good homogeneity suitable for intravenous injection enabling direct contact of artemisinin with infected erythrocytes. Chemically and physically stable artemisinin nanoparticles were obtained with excellent entrapment efficiency. In in vitro experiments, the artemisinin nanoformulation was interestingly more effective than non-formulated artemisinin. In Plasmodiumm falciparum-infected 'humanized' mice, the nanoparticles proved to be highly effective with 96% parasitemia inhibition at 10mg/kg/day, prolonging mean survival time without recrudescence. This nanoparticulate albumin-bound system allows the intravenous administration of artemisinin for the first time without harsh organic solvents or cosolvents with 100% bioavailability.
Collapse
Affiliation(s)
- Nehal Ibrahim
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| | - Hany Ibrahim
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France.
| | - Alicia Moreno Sabater
- Sorbonne Universités, UPMC Univ. Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France; INSERM, U1135, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; CNRS, ERL 8255, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France
| | - Dominique Mazier
- Sorbonne Universités, UPMC Univ. Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France; INSERM, U1135, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; CNRS, ERL 8255, CIMI-PARIS, 91 Bd de l'hôpital, F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service Parasitologie-Mycologie, Paris, France
| | - Alexis Valentin
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| | - Françoise Nepveu
- Université de Toulouse, UPS, UMR 152 (PHARMA-DEV), F-31062 Toulouse Cedex 9, France; IRD, UMR 152, F-31062 Toulouse Cedex 9, France
| |
Collapse
|
6
|
Jain SA, Basu H, Prabhu PS, Soni U, Joshi MD, Mathur D, Patravale VB, Pathak S, Sharma S. Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers. Biomaterials 2014; 35:6636-45. [DOI: 10.1016/j.biomaterials.2014.04.058] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Accepted: 04/16/2014] [Indexed: 12/30/2022]
|
7
|
Ibrahim N, Ibrahim H, Dormoi J, Briolant S, Pradines B, Moreno A, Mazier D, Legrand P, Nepveu F. Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy. Int J Pharm 2014; 464:214-24. [PMID: 24412521 DOI: 10.1016/j.ijpharm.2014.01.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 12/28/2013] [Accepted: 01/02/2014] [Indexed: 01/08/2023]
Abstract
We recently showed that the indolone-N-oxides can be promising candidates for the treatment of chloroquine-resistant malaria. However, the in vivo assays have been hampered by the very poor aqueous solubility of these compounds resulting in poor and variable activity. Here, we describe the preparation, characterization and in vivo evaluation of biodegradable albumin-bound indolone-N-oxide nanoparticles. Nanoparticles were prepared by precipitation followed by high-pressure homogenization and characterized by photon correlation spectroscopy, transmission electron microscopy, differential scanning calorimetry and X-ray powder diffraction. The process was optimized to yield nanoparticles of controllable diameter with narrow size distribution suitable for intravenous administration, which guarantees direct drug contact with parasitized erythrocytes. Stable nanoparticles showed greatly enhanced dissolution rate (complete drug release within 30 min compared to 1.5% of pure drug) preserving the rapid antimalarial activity. The formulation achieved complete cure of Plasmodium berghei-infected mice at 25mg/kg with parasitemia inhibition (99.1%) comparable to that of artesunate and chloroquine and was remarkably more effective in prolonging survival time and inhibiting recrudescence. In 'humanized' mice infected with Plasmodium falciparum, the same dose proved to be highly effective: with parasitemia reduced by 97.5% and the mean survival time prolonged. This formulation can help advance the preclinical trials of indolone-N-oxides. Albumin-bound nanoparticles represent a new strategic approach to use this most abundant plasma protein to target malaria-infected erythrocytes.
Collapse
Affiliation(s)
- Nehal Ibrahim
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France
| | - Hany Ibrahim
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France.
| | - Jerome Dormoi
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Sébastien Briolant
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Bruno Pradines
- Unité de Parasitologie, Institut de Recherche Biomédicale des Armées (IRBA), Le Pharo, 13262 Marseille, France; Unité de Recherche Maladies Infectieuses et Tropicales Emergentes (URMITE), Faculté de Médecine La Timone, Université Aix-Marseille, 13385 Marseille cedex 5, France
| | - Alicia Moreno
- Université Pierre et Marie Curie-Paris 6, UMR S945, Paris, France; Institut National de la Santé et de la Recherche Médicale, U945, Paris, France
| | - Dominique Mazier
- Université Pierre et Marie Curie-Paris 6, UMR S945, Paris, France; Institut National de la Santé et de la Recherche Médicale, U945, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service Parasitologie-Mycologie, Paris, France
| | - Philippe Legrand
- Institut Charles-Gerhardt, UMR 5253 CNRS/UM2/ENSCM/UM1, 8 rue de l'école Normale, 34296 Montpellier cedex 05, France
| | - Françoise Nepveu
- Université de Toulouse, UPS, UMR 152 (Laboratoire de pharmacochimie et pharmacologie pour le développement, Pharma-DEV), F-31062 Toulouse cedex 9, France; IRD, UMR 152, F-31062 Toulouse cedex 9, France
| |
Collapse
|